Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort
Year: 2024
Type: conference-abstract
Source: Cancer Research
Institutions: Sarah Cannon, Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Harvard University, Massachusetts General Hospital, Moffitt Cancer Center, Stanford Medicine, Stanford University, Norwalk Hospital, University of Chicago, Arvinas (United States), Pfizer (United States), University of Michigan, Michigan Medicine, U-M Rogel Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4396587114